August 20, 2017 9:27 PM ET


Company Overview of Tamir Biotechnology, Inc.

Company Overview

Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...

12625 High Bluff Drive

Suite 113

San Diego, CA 92130

United States

Founded in 1981





Key Executives for Tamir Biotechnology, Inc.

Chief Executive Officer, President, Secretary, and Director
Age: 51
Chief Financial Officer and Secretary
Age: 55
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Age: 75
Compensation as of Fiscal Year 2017.

Tamir Biotechnology, Inc. Key Developments

Tamir Biotechnology Announces Results from Pre-Clinical Investigational Study at Institute of Antiviral Research

Tamir Biotechnology announced results from a pre-clinical investigational study at the Institute of Antiviral Research at Utah State University. The study evaluated the anti-viral activity of ranpirnase in an established cell model of Zika virus infection. Overall, the study revealed that ranpirnase was active in blocking Zika virus relative to a control. In previous cell based studies, ranpirnase exhibited no cytotoxic effects at therapeutically effective dose levels. The clinical work with the Zika virus builds on years of work with other virally-caused pathologies such as Ebola. Results from a recent NIH-sponsored study on the Ebola virus gave 100% survival in ranpirnase-treated animals administered with therapeutic levels of the drug post-infection. The virus was undetectable in the serum of ranpirnase-treated mice at eight days post-infection. The company's clinical program is led by their phase II investigation of a topical formulation of ranpirnase in the treatment of HPV genital warts. This study is expected to begin enrollment in South America in February 2016. There are an estimated 14 million new and recurrent HPV infections per year in the US alone and the global HPV market is estimated to be over USD 2 billion in 2020. Ranpirnase for injection has been safely administered to over 1,000 subjects in previous oncology clinical trials.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tamir Biotechnology, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at